$590m to Moderna from HHS for mRNA ‘flu vax development
Pharmaceutical Technology
JANUARY 20, 2025
Moderna is set to receive $590m in funding from the HHS to expedite the development of mRNA-based pandemic influenza vaccines.
Mon.Jan 20, 2025
257 
Top 10 Pharma and Biotech M&As in the Past Decade
XTalks
JANUARY 20, 2025
The pharma and biotech sector has witnessed impressive growth over the past decade, driven by innovations and strategic partnerships. Among these, mergers and acquisitions (M&As) have played a pivotal role in reshaping the industry landscape, enabling companies to bolster their portfolios, enhance R&D capabilities and expand their global market reach.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AstraZeneca secures first BTK approval in first-line mantle cell lymphoma
Pharmaceutical Technology
JANUARY 20, 2025
AstraZeneca has received approval from the FDA for its BTK inhibitor, Calquence (acalabrutinib), for first-line use in MCL.
UK sees 70% increase in phase I advanced therapy clinical trials in 2024
Pharma Times
JANUARY 20, 2025
Cell and Gene Therapy Catapult reveals significant growth in UK trials
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
FDA’s START and CoGenT pilot programmes: Streamlining rare disease drug approvals
Pharmaceutical Technology
JANUARY 20, 2025
This week, at the J.P. Morgan Healthcare Conference and the Biotech Showcase, discussions underscored the growing focus on innovation in cell and gene therapies.
The Hidden Pitfalls of Searching Drug Patents on Google Patents
Drug Patent Watch
JANUARY 20, 2025
The Hidden Pitfalls of Searching Drug Patents: What You Need to Know As a professional in the pharmaceutical industry, you're likely no stranger to the importance of staying on top of the latest patent developments. But have you ever stopped to think about the potential pitfalls of searching for drug patents on Google Patents? At first glance, Google Patents may seem like a convenient and user-friendly resource for searching patent data.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Datapharm expands into US market through partnership with phactMI
Pharma Times
JANUARY 20, 2025
Collaboration aims to enhance accessibility of medicines information
Interleukin inhibitors remain a strong growth driver in dermatology
Pharmaceutical Technology
JANUARY 20, 2025
If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.
Pfizer’s PD-1 Inhibitor Sasanlimab in Combo with Standard of Care Shown to Improve Event-Free Survival in High-Risk Bladder Cancer
XTalks
JANUARY 20, 2025
Pfizer announced promising results from its Phase III trial investigating the efficacy of sasanlimab, an anti-PD-1 monoclonal antibody, in combination with standard of care Bacillus Calmette-Guerin (BCG) immunotherapy for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are BCG-nave. The Phase III CREST trial met its primary endpoint, demonstrating that as a first-line treatment, the combination significantly improved event-free survival (EFS) compared to BCG monotherapy.
Feinstein Institutes gains NIH grant to explore ghrelin for GI-ARS
Pharmaceutical Technology
JANUARY 20, 2025
Northwell Healths Feinstein Institutes for Medical Research has received a $2.9m grant from the NIH to explore the use of human ghrelin.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pfizer’s Sasanlimab in Combo with Standard of Care Improves Event-Free Survival in High-Risk Bladder Cancer
XTalks
JANUARY 20, 2025
Pfizer announced promising results from its Phase III trial investigating the efficacy of sasanlimab, an anti-PD-1 monoclonal antibody, in combination with standard of care Bacillus Calmette-Guerin (BCG) immunotherapy for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are BCG-nave. The Phase III CREST trial met its primary endpoint, demonstrating that as a first-line treatment, the combination significantly improved event-free survival (EFS) compared to BCG monotherapy.
Arrowhead’s plozasiran set for FDA review as Tryngolza challenge looms
Pharmaceutical Technology
JANUARY 20, 2025
An FDA approval later this year for Arrowheads plozasiran in FCS would put it in direct competition with Ionis Tryngolza.
The new gold standard in sequencing technology
Drug Discovery World podcast
JANUARY 20, 2025
In this sponsored DDW Sitting Down With podcast we speak to experts from Lonza and Oxford Nanopore about their collaboration to bring direct mRNA sequencing (including N1-Methyl-pseudouridine) to a regulated environment and establish the new gold standard in sequencing technology. We discuss how nanopore sequencing will be used to perform unbiased identity testing while enabling the simultaneous analyses of multiple critical quality attributes such as integrity (mRNA length and poly-A tail lengt
FDA approves Amgen’s combo therapy for colorectal cancer
Pharmaceutical Technology
JANUARY 20, 2025
Amgens LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.
Informa Connect's Patient Assistance & Access Programs (PAP)
Drug Channels
JANUARY 20, 2025
Informa Connect's Patient Assistance & Access Programs (PAP) March 18-20, 2025 | Sheraton Philadelphia Downtown PA Pre-Conference Workshops on March 17, 2025 Drug Channels readers save 10% on their registration with code 25DC10 When it comes to patient affordability, its difficult to imagine a more complex time for our industry. Navigating policy updates, disarming AFPs, considering compliance risks There are countless barriers to medication access and it remains our responsibility as an in
DDW Highlights: 20 January 2025
Drug Discovery World podcast
JANUARY 20, 2025
The latest episode of the DDW Highlightspodcast is now available to listen to below. DDWs Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of positive announcements related to the early clinical and preclinical development of immunotherapies, including an islet cell therapy for diabetes, an antibody-drug conjugate and a CAR-T therapy for multiple myeloma, and a peptide-drug conjugate and a vaccin
Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes
JAMA Internal Medicine
JANUARY 20, 2025
This cohort study compares kidney outcomes between initiation of empagliflozin vs dapagliflozin in adults with type 2 diabetes who were receiving antihyperglycemic treatment.
Lindus Health: AI instrumental for predicting trial outcomes and shaping study design
Outsourcing Pharma
JANUARY 20, 2025
We ran a Q&A With Michael Young, co-founder of Lindus Health on the challenges of 2024 and the companys goals for 2025.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Individual SGLT-2 Inhibitors and Cardiovascular and Safety Outcomes
JAMA Internal Medicine
JANUARY 20, 2025
This comparative effectiveness research study uses target trial emulation to examine the effectiveness of individual sodium-glucose cotransporter 2 (SGLT-2) inhibitors canagliflozin or dapagliflozin compared with empagliflozin using a composite outcome.
Addressing Legal Battles in the Pharma Space
Pharmaceutical Commerce
JANUARY 20, 2025
In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, explains how collaboration between compounding pharmacies, drug manufacturers, and telehealth platforms can drive success, despite the various litigations pertaining to GLP-1s that currently taking place.
Regulatory bodies placing more importance on patient centricity, says pharma executive
Outsourcing Pharma
JANUARY 20, 2025
We ran a Q&A with John Clarke, associate director in patient recruitment at Innovaderm on the changing landscape of patient centricity in terms of clinical trials and how the industry can navigate the evolving regulatory expectations around it.
The Digital Transformation Reshaping Hospitals and Medication Management
Pharmaceutical Commerce
JANUARY 20, 2025
Despite challenges surrounding communication overload, drug shortages, and cybersecurity risks, this term is revolutionizing medication management and patient care through the use artificial intelligence and predictive forecasting.
Smart search to seamless care: How AI will transform experiences in 2025
pharmaphorum
JANUARY 20, 2025
AI technology, such as GenAI and ChatGPT, is set to revolutionise experiences in 2025 across various industries, including life science. Learn more about the future of AI and its impact on the way we interact and innovate.
Pharma Pulse 1/20/25: Rare Drug Development and Chrysalis Genetics, Evaluating the Cost-Effectiveness of NSCLC Treatment & more
Pharmaceutical Commerce
JANUARY 20, 2025
The latest news for pharma industry insiders.
Life Sciences Industry Report – Part 4
pharmaphorum
JANUARY 20, 2025
Discover key insights on data analytics, wearable health devices, and AI-driven models in the life sciences industry in this informative report - Part 4. Stay informed on the latest trends and advancements shaping the industry.
FDA Recommends Disclosure of Plant Source in Draft Guidance on Labeling Plant-Based Alternatives
FDA Law Blog
JANUARY 20, 2025
By Sophia R. Gaulkin & Ritte van Laack Readers of this blog likely are familiar with the ongoing, often contentious battle over the labeling of plant-based foods (see, e.g., here , here , and here ). Nearly two years after FDA issued draft guidance on Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient Statements , on January 6, 2025, FDA released draft guidance document on plant-based labeling, Labeling Plant-Based Alternatives to Animal-Derived Foods.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Let's personalize your content